BACKGROUND: Hyperuricemia is an independent risk factor for renal progression in IgA nephropathy (IgAN). However, no study has evaluated the effect of allopurinol on the clinical outcome in hyperuricemic IgAN. METHODS: First,a retrospective cohort study of 353 IgAN patients was conducted to explore the relationship between uric acid (UA) and the progression of renal disease over a mean period of 5 years. Then, 40 hyperuricemic IgAN patients were randomized to receive allopurinol (100-300 mg/day) or usual therapy for 6 months. The study outcomes were renal disease progression and/or blood pressure. RESULTS: Hyperuricemia independently predicted renal survival at 1, 3, and 5 years after adjustment for different baseline estimated glomerular filtration rates. In the randomized controlled trial, allopurinol did not significantly alter renal progression or proteinuria. The antihypertensive drug dosage was reduced in 7 of 9 cases with hypertension in the allopurinol group compared to 0 of 9 cases in the control group (p < 0.01). UA levels correlated with mean arterial pressure in normotensive patients (r = 0.388, p < 0.001). CONCLUSION: Hyperuricemia predicts the progression of IgAN independently of baseline estimated glomerular filtration rate. Allopurinol may improve the control of blood pressure. Further studies are required to explore the effects of lowering UA on renal protection in IgAN.
RCT Entities:
BACKGROUND:Hyperuricemia is an independent risk factor for renal progression in IgA nephropathy (IgAN). However, no study has evaluated the effect of allopurinol on the clinical outcome in hyperuricemicIgAN. METHODS: First,a retrospective cohort study of 353 IgANpatients was conducted to explore the relationship between uric acid (UA) and the progression of renal disease over a mean period of 5 years. Then, 40 hyperuricemicIgANpatients were randomized to receive allopurinol (100-300 mg/day) or usual therapy for 6 months. The study outcomes were renal disease progression and/or blood pressure. RESULTS:Hyperuricemia independently predicted renal survival at 1, 3, and 5 years after adjustment for different baseline estimated glomerular filtration rates. In the randomized controlled trial, allopurinol did not significantly alter renal progression or proteinuria. The antihypertensive drug dosage was reduced in 7 of 9 cases with hypertension in the allopurinol group compared to 0 of 9 cases in the control group (p < 0.01). UA levels correlated with mean arterial pressure in normotensive patients (r = 0.388, p < 0.001). CONCLUSION:Hyperuricemia predicts the progression of IgAN independently of baseline estimated glomerular filtration rate. Allopurinol may improve the control of blood pressure. Further studies are required to explore the effects of lowering UA on renal protection in IgAN.
Authors: Marian Goicoechea; Soledad García de Vinuesa; Ursula Verdalles; Caridad Ruiz-Caro; Jara Ampuero; Abraham Rincón; David Arroyo; José Luño Journal: Clin J Am Soc Nephrol Date: 2010-06-10 Impact factor: 8.237
Authors: Todd S Perlstein; Olga Gumieniak; Paul N Hopkins; Laine J Murphey; Nancy J Brown; Gordon H Williams; Norman K Hollenberg; Naomi D L Fisher Journal: Kidney Int Date: 2004-10 Impact factor: 10.612
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: John Kanellis; Susumu Watanabe; Jin H Li; Duk Hee Kang; Ping Li; Takahiko Nakagawa; Ann Wamsley; David Sheikh-Hamad; Hui Y Lan; Lili Feng; Richard J Johnson Journal: Hypertension Date: 2003-05-12 Impact factor: 10.190
Authors: Nicolas Macías; Marian Goicoechea; M S García de Vinuesa; Ursula Verdalles; Jose Luño Journal: Curr Rheumatol Rep Date: 2013-12 Impact factor: 4.592
Authors: Hakan Nacak; Merel van Diepen; Abdul R Qureshi; Juan J Carrero; Theo Stijnen; Friedo W Dekker; Marie Evans Journal: Nephrol Dial Transplant Date: 2015-07-16 Impact factor: 5.992
Authors: Ali Bakan; Alihan Oral; Omer Celal Elcioglu; Mumtaz Takir; Osman Kostek; Abdullah Ozkok; Semih Basci; Abdullah Sumnu; Savas Ozturk; Murat Sipahioglu; Aydın Turkmen; Luminita Voroneanu; Adrian Covic; Mehmet Kanbay Journal: Int Urol Nephrol Date: 2015-03-12 Impact factor: 2.370